AVEO Pharmaceuticals — JP Morgan 2015 Global Healthcare Conference
33 slides from AVEO Pharmaceuticals's conference presentation, Jan 13, 2015

Slide 1: JP Morgan 2015 Global Healthcare Conference
JP Morgan 2015 Global Healthcare Conference JANUARY 15, 2015 Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate

Slide 3: Path Forward: Goals and Milestones
January 12, 2015 AVEO Path Forward: Goals and Milestones AVEO Has a Robust Pipeline and Streamlined Organization Tivozanib VEGFR 1,2,3 TKI Evaluate potential development strategies for registration - EU MAA (RCC) - CRC biomarker-driven studies - RCC studies Present biomarker data Ficlatuzumab HGF MA

Slide 4: Go Forward Strategy
January 12, 2015 AVEO Go Forward Strategy Optimally Leveraging Biomarker Insights and Partnership Resources to Advance Our Portfolio of Development-Stage Assets

Slide 5: Leveraging Biomarkers and Partnerships to Advance Robust Pipeline
Program Pathway Development Candidate Preclinical Phase 1 Phase 2 Phase 3 Rights GDF-15 Biomarker Cachexia Potential EU File RCC NRG-1 Biomarker Solid Tumors Serum Proteomic Biomarker NSCLC Angiogenesis Biomarkers CRC AVEO is Leveraging Biomarkers and Partnerships to Advance its Robust Pipeline of A

Slide 6: Tivozanib
Tivozanib A POTENT , SELECTIVE , LONG HALF - LIFE INHIBITOR OF VA SCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 1, 2, AND 3 RECEPTORS

Slide 7: Tivozanib – VEGFR 1, 2 & 3 Tyrosine Kinase Inhibitor
Tivozanib – VEGFR 1, 2 & 3 Tyrosine Kinase Inhibitor • Potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities 1,2 • Patent term: 2022 (composition of matter) with potential extension to 2027 • Orphan drug d

Slide 8: Ophthotech Research and Option Agreement: Nov. 2014
January 12, 2015 8 Ophthotech Research and Option Agreement: Nov. 2014 Agreement Research and Exclusive Option Agreement for Non-Oncology Disease of the Eye Territory Worldwide ex-Asia Upfront $500,000 Option Term Milestones $2M at IND filing and $6M based upon the achievement of specified R&D, busi

Slide 9: Tivozanib Preclinical Activity in Ocular Models
January 12, 2015 9 Tivozanib Preclinical Activity in Ocular Models Compared to the vehicle-treatment, tivozanib suppressed the development of CNV lesions and led to a significant regression of established CNV reducing the affected areas by 80.7% and 67.7% respectively

Slide 10: Current Anti-VEGF Market: Expanding Multi-Billion Dollar Opportunity
Current Anti-VEGF Market: Expanding Multi-Billion Dollar Opportunity Annual Global Branded Anti-VEGF Sales* 64 48 : 38 29 23 1.8 1.2 om a 2010 21 2012 213 2006 2007 2008 2009 “Ophenctech Pearelesirace Sales in First 12 Months FollowingLaunch

Slide 11: Evaluating Potential for MAA Filing for RCC
January 12, 2015 Evaluating Potential for MAA Filing for RCC • Met primary PFS endpoint of superiority vs sorafenib • First H2H RCC pivotal trial to show superiority over another VEGF TKI • Demonstrated differentiated safety profile • OS confounded by crossover • Median OS similar to historical TKI

Slide 12: Tivozanib Biomarker Study in Colorectal Cancer
January 12, 2015 • Interim results (ESMO 2014) suggest that tivozanib+mFOLFOX6 is comparable to bevacizumab+mFOLFOX6 in the ITT population, with an acceptable safety profile. • PFS: 9.4 (Tivo) vs 10.7 (Bev) months; HR=1.091, p=0.706 • ORR: 45% (Tivo) vs. 43% (Bev), p=0.718 • Final pre-specified biom

Slide 13: Ficlatuzumab
A POTENT HEPATOCYTE GROWTH FACTOR (HGF) INHIBITORY ANTIBODY THAT BINDS TO THE HGF LIGAND WITH HIGH AFFINITY AND SPECIFICITY TO INHIBIT THE BIOLOGICAL ACTIVITIES OF HGF/c-MET PATHWAY

Slide 14: Ficlatuzumab – Humanized IgG1k MAb Inhibitor of HGF
• A Favorable Profile to In-Class Antibodies – High affinity (pM) and slow off-rate for HGF – High potency (nM) inhibiting all biological activities of HGF, including autocrine/paracrine activation loops – In vivo preclinical efficacy superior to in-class antibodies Ficlatuzumab – Humanized IgG1k MA

Slide 15: Biodesix Partnership: April 2014
January 12, 2015 Biodesix Partnership: April 2014 AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic – Unique collaboration where the diagnostic company provides funding for POC clinical development in NSCLC • Biodesix will fund up to $15 million of th

Slide 16: Ficlatuzumab Randomized Phase 2 Study: Exploratory Analysis Results
Ficlatuzumab Randomized Phase 2 Study (P06162): Exploratory Analysis Results* VeriStrat may be a predictive biomarker for the combination of ficlatuzumab EGFR TKI over EGFR TKI alone Observation to be confirmed in the Phase 2 FOCAL study, initiated in 2014 * Mok et al ESMO 2014 VeriStrat Poor (VSP)

Slide 17: FOCAL Study – Confirmatory Phase 2
January 12, 2015 FOCAL Study – Confirmatory Phase 2 A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label st L

Slide 18: AV-203
A POTENT ERBB3 (HER3) INHIBITORY ANTIBODY DESIGNED TO INHIBIT BOTH LIGAND- DEPENDENT AND LIGAND-INDEPENDENT ERBB3 SIGNALING

Slide 19: AV-203: Superhumanized IgG1k MAb Inhibitor of ERBB3
January 12, 2015 AV-203: Superhumanized IgG1k MAb Inhibitor of ERBB3 • Potent high affinity NRG-1/HRG binding inhibition – Exclusively blocks ERBB3 signaling – Potential for inducing ADCC – Prevents NRG-1/HRG induced proliferation – Opportunity to explore combinations with HER2 and EGFR Targeted The

Slide 20: Biogen Idec Agreement: March 2014
January 12, 2015 Biogen Idec Agreement: March 2014 • Actively pursuing partnership to advance development • AVEO reacquired AV-203 worldwide rights from Biogen Idec – NRG-1/HRG positive tumors – Combinations with EGFR and HER2 targeted inhibitors – Combination with chemotherapy in chemotherapy resis

Slide 21: Phase 1 AV-203 Dose-Escalation, Monotherapy Study
January 12, 2015 Phase 1 AV-203 Dose-Escalation, Monotherapy Study Completed* • 22 subjects enrolled – Tumor types: 4 NSCLC (3 sq, 1 adeno); 4 CRC; 2 sq cell skin; one each ovarian, peritoneal, SCLC, endometrioid, osteosarcoma, HCC, pancreatic, neuroendocrine, bladder, mesothelioma, SCCHN, cervical

Slide 22: Potential First-in-Class GDF15 Inhibitory Antibody
POTENTIAL FIRST-IN-CLASS GDF15 INHIBITORY ANTIBODY

Slide 23: Cachexia Represents a Significant Unmet Medical Need
Cancer Congestive Heart Failure Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Cachexia (Wasting Syndrome) associated with several underlying chronic illnesses and characterized by loss of muscle mass and strength, loss of whole body fat, inflammation, anemia, etc. ~400,000 pts In US ~

Slide 24: GDF15 – Driver of Cachexia (Wasting Syndrome)
24 GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: • Elevated in cachectic models and patients (vs. non-cachectic) • Administration of GDF15 induces cachexia • Inhibition of GDF15 reverses cachexia

Slide 25: GDF15 – Driver of Cachexia (Wasting Syndrome)
25 GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: GDF15 Levels – Patient Samples GDF15 Levels – Murine Models Inhibition of GDF15 reverses cachexia Administration of GDF15 induces cachexia Elevated in cachectic models and patients (vs. non-cachectic)

Slide 26: GDF15 – Driver of Cachexia (Wasting Syndrome)
26 GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: Elevated in cachectic models and patients (vs. non-cachectic) Administration of GDF15 induces cachexia Inhibition of GDF15 reverses cachexia ***

Slide 27: GDF15 – Driver of Cachexia (Wasting Syndrome)
27 GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: Elevated in cachectic models and patients (vs. non-cachectic) Administration of GDF15 induces cachexia Inhibition of GDF15 reverses cachexia

Slide 28: GDF15 – Driver of Cachexia (Wasting Syndrome)
28 GDF15 – Driver of Cachexia (Wasting Syndrome) Proof-of-Concept: Inhibition of GDF15 reverses cachexia Administration of GDF15 induces cachexia Elevated in cachectic models and patients (vs. non-cachectic)

Slide 29: First-in-Class, Differentiated Approach to Cachexia
First-in-Class, Differentiated Approach to Cachexia • AV-380: Potent humanized GDF15 inhibitory MAb – Unique mechanism of action • Increase calorie/food intake • Reverse body weight loss • Restore normal body composition • Mechanism of action different from: – Hormonal/Metabolic agents (i.e. ghrelin

Slide 30: Financials and Summary
Financials and Summary January 12, 2015

Slide 31: Financials Highlights
Financials Highlights • Streamlined operations – Exited long term facilities lease – Eliminated research function to focus on clinical and BD functions • Headcount reduction from 60 to 20 • Expected to reduce annual compensation expenses by ~$6 million • Will reduce AVEO’s facilities requirements by

Slide 32: Poised to Unlock the Potential of its Robust Pipeline
Program Pathway Development Candidate Preclinical Phase 1 Phase 2 Phase 3 Rights GDF-15 Biomarker Cachexia Potential EU File RCC NRG-1 Biomarker Solid Tumors Serum Proteomic Biomarker NSCLC Angiogenesis Biomarkers CRC AVEO is Poised to Unlock the Potential of its Robust Pipeline of Assets by Leverag

Slide 33: JP Morgan 2015 Global Healthcare Conference
33 JP Morgan 2015 Global Healthcare Conference JANUARY 15, 2014
Source: SEC EDGAR · 8-K filed Jan 13, 2015
More decks from AVEO Pharmaceuticals Inc
Investor Presentation (August 2022)44 slides · Aug 9, 2022
Investor Presentation (May 2022)46 slides · May 6, 2022
Investor Presentation (March 2022)47 slides · Mar 14, 2022
Investor Presentation (July 2021)47 slides · Jul 16, 2021
Investor Presentation (July 2020)26 slides · Jul 6, 2020
Corporate Update (May 2020)25 slides · May 29, 2020